Abiopharma

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

eMaint Named a Leader in the Verdantix Green Quadrant for CMMS - One of Only Two Vendors Also Recognized for EAM

Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

CollPlant to Present at the 2025 International Conference on Biofabrication

New Form 8-K - Zymeworks Inc. Filed: 2025-09-02 AccNo: 0001193125-25-193351 Size: 165 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-09-02 AccNo: 0001654954-25-010241 Size: 7 MB

BD Expands Peripheral Artery Disease Awareness Efforts with Love Your Limbs Community Screening Initiative

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

New Form 6-K - ALTERITY THERAPEUTICS LTD Filed: 2025-09-02 AccNo: 0001213900-25-082896 Size: 123 KB